Subcutaneous tarlatamab demonstrates safety and antitumor activity in extensive-stage small cell lung cancer

Subcutaneous administration of tarlatamab was reported as well tolerated and showed preliminary antitumor activity in patients with previously treated extensive‑stage small cell lung cancer (ES‑SCLC) in the phase 1b DeLLphi‑308 trial. The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer, where investigators highlighted that the study enrolled individuals who had received prior therapy for ES‑SCLC and received tarlatamab via a subcutaneous route.

The early‑phase data suggest that tarlatamab may offer a manageable safety profile while eliciting signs of clinical efficacy in this heavily pretreated population. Researchers noted that the results support further clinical evaluation of the agent in larger studies to confirm its therapeutic potential and define its role within the treatment landscape for extensive‑stage small cell lung cancer.